An aerosol of CaNa2E.D.T.A. ("mosatil") has been administered in hospital to two groups of five men who had been working on a lead smelter and exposed to lead in air concentrations of the order of 0*6 to 1-25 mg. of lead per m3. Five patients each inhaled 0-6 g. of CaNa2E.D.T.A.
on seven successive days, and 2-4 g. on the ninth day. An average of 21P6 mg. of lead was excreted during the treatment.
Five patients given 2-4 g. of CaNa2E.D.T.A. every other day for eight days excreted an average of 14*2 mg. of lead each during treatment. The urinary coproporphyrin level fell to normal in both groups.
In recent years aerosol therapy has found an increasing use. Its advantage is that the fine aerosol particles are absorbed directly from the lungs into the blood stream through the alveolar epithelium without discomfort to the patient, and it can be given simultaneously to groups of patients. Alkaline mineral waters have been used in this way for silicosis (Beckmann and Reif, 1955) . The disadvantages of aerosol therapy are the need for special equipment and the uncertainty about the dose received by the patient. Sometimes drying of the mucous membranes may be uncomfortable for the patient.
The value of CaNa2E.D.T.A. in the treatment and prevention of lead poisoning is well recognized (Teisinger and Srbova, 1956; Buckup and Remy, 1958; Unseld, 1958) . It may also be used as a diagnostic test (Albahary, Truhaut, and Boudene, 1958;  Savicevic, Petrovic, / Stankovic, and Djordjevic, 1959). Teisinger and Srbova (1956) to 10 patients as an aerosol generated by a Draeger aerosol apparatus. The patients were working in a smelting plant with an atmospheric concentration of 0-6-1-25 mg. lead oxide per mi3. During treatment the nasal mucosa became dry and this was attributed to the warm air from the apparatus and the high Ca content of the drug. All the patients were in hospital during treatment and for the two subsequent days. Daily analyses were carried out of the urinary lead and coproporphyrin and a haematogram including stippled cells and reticulocytes was drawn. Blood lead was determined two to three times during the period of treatment.
Results
In Fig. 1 the values for urinary lead and coproporphyrin in the first group are shown. The excretion of lead rises as soon as inhalation therapy starts, drops sharply when it is discontinued, and rises when it is resumed. The daily fluctuations in lead excretion related to treatment on alternate days is shown more strikingly in the second group (Fig. 2) . The total lead excreted falls steadily and remains at a constant low level for the three days after treatment stopped. Urinary coproporphyrin shows a fall in both groups. Blood lead levels, originally 201 
